PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
38 hedge funds and large institutions have $3.89M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.
Holders
38
Holders Change
-11
Holders Change %
-22.45%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
12
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
CA
1
CHI Advisors
New York
|
$0 |
| 2 |
NLG
2
New Legacy Group
New York
|
$0 |
| 3 |
3
Marshall Wace
London,
United Kingdom
|
$0 |
| 4 |
4
Citadel Advisors
Miami,
Florida
|
$0 |
| 5 |
5
Stifel Financial
St. Louis,
Missouri
|
$2K |
